Studies on the usefulness of intranasal inactivated influenza vaccines
- PMID: 20493820
- DOI: 10.1016/j.vaccine.2010.05.019
Studies on the usefulness of intranasal inactivated influenza vaccines
Abstract
Intranasal inactivated influenza vaccines have the advantage over parenteral vaccines in that they are not associated with the pain of an injection. However, they would be most useful if they were available for all age groups, including high-risk groups, and also would provide cross-protection against variant virus strains. Supporting the latter objective is our observation that intranasal inactivated vaccines provide cross-protection against variants within a subtype of the A virus (or variants within the B virus), together with inducing highly cross-reactive secretory-IgA antibodies to viral HA and the weakly cross-reactive IgG antibodies in the respiratory tract. This review summarizes the most important observations of our studies on intranasal inactivated influenza vaccines, which have been ongoing since 1987. These studies center on a mouse model of influenza in which mice are immunized intranasally with inactivated vaccines mixed with a cholera toxin B subunit adjuvant and then infected with mouse-adapted influenza viruses.
(c) 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670. J Med Virol. 2010. PMID: 19950232
-
Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.J Immunol. 1992 Aug 1;149(3):981-8. J Immunol. 1992. PMID: 1634780
-
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10. Virology. 2008. PMID: 18786689
-
Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.Jpn J Infect Dis. 2005 Aug;58(4):195-207. Jpn J Infect Dis. 2005. PMID: 16116250 Review.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
-
Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.Front Immunol. 2019 Mar 29;10:646. doi: 10.3389/fimmu.2019.00646. eCollection 2019. Front Immunol. 2019. PMID: 30984200 Free PMC article.
-
Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.Vaccines (Basel). 2015 Mar 5;3(1):148-71. doi: 10.3390/vaccines3010148. Vaccines (Basel). 2015. PMID: 26344951 Free PMC article. Review.
-
Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.PLoS One. 2013 Aug 8;8(8):e70527. doi: 10.1371/journal.pone.0070527. eCollection 2013. PLoS One. 2013. PMID: 23950951 Free PMC article.
-
Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.Hum Vaccin Immunother. 2014;10(8):2175-87. doi: 10.4161/hv.29269. Hum Vaccin Immunother. 2014. PMID: 25424921 Free PMC article. Review.
-
Intranasal Immunization of Mice to Avoid Interference of Maternal Antibody against H5N1 Infection.PLoS One. 2016 Jun 9;11(6):e0157041. doi: 10.1371/journal.pone.0157041. eCollection 2016. PLoS One. 2016. PMID: 27280297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous